期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 14, 期 4, 页码 479-488出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.14.4.479
关键词
ADL-8-2698; alvimopan; Entereg(TM); opioid antagonist; opioid-induced bowel dysfunction; post-operative ileus
Alvimopan is a synthetic peripherally restricted p-receptor opioid antagonist. Alvimopan has a greater affinity for the p-receptor than the kappa- or sigma-opioid receptors (K-i = 0.77 nM). The polarity of the molecule limits gastrointestinal absorption and central nervous system penetration. It has limited systemic bioavailability and higher affinity for the p-opioid receptor than naloxone (K-i = 3.7 nM). Completed Phase III trials suggest efficacy in accelerating the recovery of gastrointestinal function after abdominal surgery. Adverse events with all doses have been similar to placebo groups. Further efficacy in alleviating opioid-induced bowel dysfunction in patients with chronic opioid usage has also been demonstrated. This evidence-based review assesses this new drug and discusses its potential role in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据